Nab-paclitaxel — drug

Regulatory

Approvals (0)

Each record names the authority, jurisdiction, indication text and status. A drug approved in one jurisdiction for one indication is not 'approved' in general.

Data not yet available

No regulatory approval recorded. Absence here is not evidence of absence: only ingested jurisdictions are covered.

What CancerIndex knows

Curated evidence below
Sources

Derived

Development pipeline

Most advanced stage across all cancers, then per top-level cancer reached through trial conditions or approval indications. Approval in any ingested jurisdiction outranks trial phase; counts are interventional studies.

Scope	Stage	Max phase	Active	Recruiting	Phase 3	Trials	Jurisdictions	First approval	First trial
All cancers	Phase4	Phase 4	281	146	111	748	—	—	2003-09
Malignant Pancreatic Neoplasm	Phase4	Phase 4	87	40	23	230	—	—	Nov 1, 2006
Malignant Breast Neoplasm	Phase4	Phase 4	51	24	32	151	—	—	Jun 1, 2004
Malignant Lung Neoplasm	Phase4	Phase 4	46	22	21	110

Curated evidence

Clinical evidence (2)

CIViC items in which this therapy appears, grouped by cancer context, then molecular profile. 50 items per page.

civicCuratedShowing 1–2 of 2 evidence items · levels, directions and significance as curated at the source; each row links to its CIViC record.

Therapy	Cancer	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
PIK3CA Mutation1
Nab-paclitaxel	HER2-Positive Breast Carcinoma

Clinical trials

Trials with this intervention (753)

Most recently updated first, 50 per page.

clinicaltrialsPublishedShowing 51–100 of 753 studies · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT06132958	Sacituzumab Tirumotecan (MK-2870) in Post Platinum and Post Immunotherapy Endometrial Cancer (MK-2870-005)(TroFuse-005)	active not recruiting	Phase 3	710	Merck Sharp & Dohme LLCINDUSTRY	31	Aug 28, 2026	clinicaltrials
NCT05722015	A Study of Subcutaneous (SC) Pembrolizumab Coformulated With Berahyaluronidase Alfa (MK-3475A) vs Intravenous Pembrolizumab in Adult Participants With Metastatic Non-small Cell Lung Cancer (NSCLC) (MK-3475A-D77)